SVF Vaccines AB, a portfolio company of Karolinska Development AB, has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B (HBV) and D viruses (HDV).
The multidrug resistance of methicillin-resistant Staphylococcus aureus (MRSA) makes it a global threat to public health, and the current first-line treatment for MRSA, the glycopeptide vancomycin, can have toxic effects on the kidney and ear.
Smartbax GmbH has announced the successful first closing of its €4.7 million (US$5.4 million) pre-series A financing round to support development of its next-generation antibiotics against multidrug-resistant (MDR) bacteria. A second closing of the round remains open to investors.
In vaccine development, one might think that targeting multiple epitopes increases the likelihood of improving outcomes. However, when several immunogens are administered together, the immune system does not always generate antibodies against all of them. Two parallel studies have overcome this challenge by using multiple simultaneous immunogens against HIV, effectively triggering various types of broadly neutralizing antibody (bnAb) precursors in two different preclinical animal models.
As part of global efforts to develop next-generation antibiotics to overcome the growing problem of bacterial resistance to existing drugs, researchers at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences prepared various derivatives of the dimethylcysteamine form of pleuromutilin, a naturally occurring diterpenoid.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized prodrugs of deuterated baloxavir marboxil derivatives acting as cap-dependent endonuclease (CEN) (influenza virus) inhibitors reported to be useful for the treatment of influenza viral infections.
In their efforts to develop next-generation antibiotics, researchers from Hunan University and collaborators designed amidated oligopyridinium peptidomimetics.
Shenzhen Bay Laboratory has synthesized fused ring derivatives acting as dihydrofolate reductase (DHFR) (bacterial) inhibitors reported to be useful for the treatment of cancer, bacterial, fungal, nematode and viral infections.
Glycovax Pharma Inc. has entered into a strategic collaboration with the National Research Council of Canada (NRC) and the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa infections, with expected utility for patients with cystic fibrosis and hospitalized individuals at risk of nosocomial infections.
Merck Sharp & Dohme LLC (MSD) has synthesized new N-oxide derivative targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of HIV infection.
RSS
